Patents by Inventor John H. McDonald, III

John H. McDonald, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing bis-indoly macrocycles
    Patent number: 6057440
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R.sub.1, R.sub.2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: May 2, 2000
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Synthesis of indolymaleimides
    Patent number: 6037475
    Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometalic-3-indole in the presence of a transition metal catalyst.
    Type: Grant
    Filed: February 11, 1999
    Date of Patent: March 14, 2000
    Assignee: Eli Lilly & Company
    Inventors: Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Andrew Neel
  • Synthesis of indolylmaleimides
    Patent number: 5919946
    Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Neel
  • Synthesis of indolylmaleimides
    Patent number: 5859261
    Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: January 12, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Andrew Neel
  • Protein kinase C inhibitors
    Patent number: 5843935
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: July 12, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Process for preparing bis-indolyl macrocycles
    Patent number: 5821365
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R.sub.1, R.sub.2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Therapeutic treatment of cancer with Protein Kinase C inhibitors
    Patent number: 5780461
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals. The compounds of the present invention can be used to treat cancer and inhibiting tumor growth in mammals.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: July 14, 1998
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Process for preparing BIS-indolyl macrocycles
    Patent number: 5739322
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R1, R2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: April 14, 1998
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase C inhibitors
    Patent number: 5719175
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: February 17, 1998
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase C inhibitors
    Patent number: 5698578
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: October 21, 1996
    Date of Patent: December 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase C inhibitors
    Patent number: 5696108
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: December 9, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Methods of treating diabetic mellitus and its complications
    Patent number: 5674862
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 7, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase C inhibitors
    Patent number: 5672618
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 30, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Michael Paal, Theo Schotten, Wolfgang Stenzel
  • Protein kinase C inhibitors
    Patent number: 5668152
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 16, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Gerd Ruhter, Theo Schotten
  • Protein kinase C inhibitors
    Patent number: 5661173
    Abstract: The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 26, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III
  • Protein kinase C inhibitors
    Patent number: 5624949
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: April 29, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Process for preparing bis-indolyl macrocycles
    Patent number: 5621098
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## wherein R.sub.1, R.sub.2, X, W, and Y are as defined in the specification. The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase c inhibitors
    Patent number: 5552396
    Abstract: This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
  • Protein kinase C inhibitors
    Patent number: 5545636
    Abstract: The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: August 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: William F. Heath, Jr., John H. McDonald, III, Michael Paal, Gerd R uhter, Theo Schotten, Wolfgang Stenzel
  • 3-(substituted)-1-carba(dethia)-3-cephems
    Patent number: 5128336
    Abstract: Cephalosporin and 1-carba(1-dethia)cephalosporin antibiotics substituted in the 3-position with, inter alia, alkyl, alkenyl and alkynyl, are provided via process comprising conversion of a cephalosporin or 1-carba(1-dethia)-3-cephem substituted in the 3-position with halogen or a sulfonyloxy ester with Pd(O) mediated alkylation with organostannanes.
    Type: Grant
    Filed: May 1, 1989
    Date of Patent: July 7, 1992
    Assignee: Eli Lilly and Company
    Inventors: Gwendolyn K. Cook, John H. McDonald, III